EUCTR2013-000208-41-ES进行中（未招募）不适用
A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/week or 300 mg/week) as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a. Have the ability to understand, and having understood, provide written informed consent to comply with the treatment protocol.
- •b. Male or female aged 18-60 years (inclusive).
- •c. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for cocaine dependence as determined by the Structured Clinical Interview (SCID) in screening.
- •d. Seek treatment for cocaine dependence.
- •e. Provide at least four urine samples and have at least one cocaine-positive urine sample during the two-week screening period as measured by an on-site, qualitative benzoylecgonine (BE) assay.
- •f. Have a home address and can give contact locator information.
- •g. Are, in the opinion of the investigator, likely to complete the 12-week treatment phase of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 210
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a. Meet DSM-IV-TR criteria for current dependence on any psychoactive substance other than cocaine, alcohol, nicotine, benzodiazepines, or marijuana OR have physiological dependence on alcohol requiring detoxification.
- •b. Have all the available urine tests positive for opiates during the 2 weeks screening period (episodic urine tests positive for opiates are allowed).
- •c. Are currently treated with an opiate-substitute (buprenorphine or methadone) maintenance treatment or received therapy with any opiate-substitute within 90 days preceding screening.
- •d. Have one or more severe psychiatric disorders as determined by the Mini International Neuropsychiatric Interview (MINI) such as psychosis, schizophrenia, bipolar disease, major depression, or eating disorders in screening.
- •e. Have one or more major neurologic disorders such as dementia or organic brain disease.
- •f. Have other serious medical illnesses or other potentially life threatening or progressive medical illness that may compromise subject safety or study conduct as determined by the site MD.
- •g. Had previous suicidal attempt or current suicidal risk as determined by the site MD
- •h. Have liver function tests (ALT, AST) greater than x3 times upper limit of normal (ULN) or any other clinically significant abnormal laboratory value during the screening period as determined by the site MD.
- •i. Have known allergy or hypersensitivity to natural or recombinant butyrylcholinesterase (BChE), human serum albumin (HSA) or any other component of the formulation.
- •j. Current court mandated cocaine use treatment.
- •k. Have been treated for cocaine addiction within the 30 days preceding screening.
- •l. Are unable to complete the study protocol because of probable incarceration or relocation from the clinical area.
- •m. Have taken any investigational drugs within 60 days preceding screening.
- •n. Have participated in an experimental trial assessing a cocaine vaccine anytime before study screening.
- •o. Are currently exposed to or have been exposed to pesticides or any other organophosphates (e.g., agricultural workers) within 60 days preceding screening.
- •p. Women of child-bearing potential who do not practice an acceptable method of birth control.
- •q. Pregnant or nursing women.
研究者
相似试验
进行中（未招募）
不适用
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study ToEvaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement.Revised Protocol 02, Incorporating Administrative Letters 01 and 02 and Amendment 02 (v2.0, dated 17-oct-2008)EUCTR2007-005959-42-ATBristol Myers Squibb International Corporation485
进行中（未招募）
不适用
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement. Revised Protocol 02, Incorporating Administrative Letters 01 and 02 and Amendment 02 (v2.0, dated 17-oct-2008)EUCTR2007-005959-42-ITBristol Myers Squibb International Corporation485
进行中（未招募）
1 期
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study ToEvaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement.Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, de 12 semanas de duración, para evaluar la eficacia y la seguridad de la terapia con aripiprazol como adyuvante en el tratamiento de la manía en pacientes con trastorno bipolar I tratados con valproato o litio y que precisan mejoría clínica adicionalBipolar I Mania (manic or mixed episode)Mania Bipolar I (episodio maníaco o mixto)MedDRA version: 9.1Level: LLTClassification code 10026749Term: ManiaEUCTR2007-005959-42-ESBristol Myers Squibb International Corporation485
进行中（未招募）
不适用
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study ToEvaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement.Revised Protocol 02, Incorporating Administrative Letters 01 and 02 and Amendment 02 (v2.0, dated 17-oct-2008)Bipolar I Mania (manic or mixed episode)MedDRA version: 9.1Level: LLTClassification code 10026749Term: ManiaEUCTR2007-005959-42-PLBristol Myers Squibb International Corporation485
进行中（未招募）
不适用
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study ToEvaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement.Revised Protocol 02, Incorporating Administrative Letters 01 and 02 and Amendment 02 (v2.0, dated 17-oct-2008)EUCTR2007-005959-42-GRBristol Myers Squibb International Corporation485